UCL School of Pharmacy, London, UK.
National Institute for Health Research (NIHR) Biomedical Research Centre at Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of Ophthalmology, London, UK.
Br J Pharmacol. 2017 Dec;174(23):4205-4223. doi: 10.1111/bph.14024. Epub 2017 Oct 10.
The eye is a highly specialized organ that is subject to a huge range of pathology. Both local and systemic disease may affect different anatomical regions of the eye. The least invasive routes for ocular drug administration are topical (e.g. eye drops) and systemic (e.g. tablets) formulations. Barriers that subserve as protection against pathogen entry also restrict drug permeation. Topically administered drugs often display limited bioavailability due to many physical and biochemical barriers including the pre-corneal tear film, the structure and biophysiological properties of the cornea, the limited volume that can be accommodated by the cul-de-sac, the lacrimal drainage system and reflex tearing. The tissue layers of the cornea and conjunctiva are further key factors that act to restrict drug delivery. Using carriers that enhance viscosity or bind to the ocular surface increases bioavailability. Matching the pH and polarity of drug molecules to the tissue layers allows greater penetration. Drug delivery to the posterior segment is a greater challenge and, currently, the standard route is via intravitreal injection, notwithstanding the risks of endophthalmitis and retinal detachment with frequent injections. Intraocular implants that allow sustained drug release are at different stages of development. Novel exciting therapeutic approaches include methods for promoting transscleral delivery, sustained release devices, nanotechnology and gene therapy.
眼睛是一个高度专业化的器官,容易受到各种病理学的影响。局部和全身疾病都可能影响眼睛的不同解剖区域。眼部药物给药的最微创途径是局部(例如眼药水)和全身(例如片剂)制剂。作为防止病原体进入的保护屏障也限制了药物渗透。由于许多物理和生化屏障,包括角膜前泪膜、角膜的结构和生物物理特性、可容纳在隐窝中的有限体积、泪液引流系统和反射性流泪,局部给予的药物往往显示出有限的生物利用度。角膜和结膜的组织层是进一步限制药物递送的关键因素。使用增强粘度或与眼表面结合的载体可以提高生物利用度。使药物分子的 pH 值和极性与组织层匹配可以允许更大的穿透。将药物递送到后节是一个更大的挑战,目前,标准途径是通过玻璃体内注射,尽管频繁注射会有眼内炎和视网膜脱离的风险。允许持续释放药物的眼内植入物处于不同的开发阶段。新颖令人兴奋的治疗方法包括促进经巩膜递送的方法、持续释放装置、纳米技术和基因治疗。